medigraphic.com

1999, Número 2

<< Anterior

Enf Infec Microbiol 1999; 19 (2)


Fiebre asociada a neutropenia inducida por quimioterapia: revisión de las actualidades terapéuticas
La roxitromicina reduce el riesgo de nuevos eventos en la cardiopatía isquémica
La evaluación clínica es inexacta para el diagnóstico de neumonía adquirida en la comunidad
La erradicación del Helicobacter pylori antes del tratamiento con antiinflamatorios no esteroides previene el desarrollo de úlceras
El factor estimulante de colonias de granulocitos acelera la curación de la infección del pie diabético
Epidemiología del astrovirus en la Ciudad de México
Interferón alfa 2b solo o en combinación con ribavirina en pacientes con hepatitis C crónica: como tratamiento inicial (estudio A) o como tratamiento de recaída (estudio B)
Los enfermos no bacilíferos pueden transmitir la tuberculosis

Young SD, Feld R,Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, Metlay JP, Kapoor WN, Fine MJ, Chan FK, Sung JJ, Chung SC, Gough A, Clapperton M, Rolando N, Guerrero ML, Noel JS, Mitchell DK, Calva JJ, McHutchison JG, Davis GL, Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de León A, Daley CL, Small PM

Idioma: Español
Referencias bibliográficas: 64
Paginas: 90-110
Archivo PDF: 107.16 Kb.


FRAGMENTO

El número de pacientes con cáncer que padecen neutropenia inducida por quimioterapia crece continuamente a medida que aumentan nuevas indicaciones para el tratamiento sistémico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73. Estos lineamientos fueron compilados por un grupo de expertos representantes de la Sociedad Americana de Enfermedades Infecciosas, y proporcionan claras recomendaciones para el uso de antimicrobianos en pacientes con neutropenia febril. Se valora la calidad de la evidencia utilizada para estas recomendaciones y la lista de referencias es una excelente fuente de información.

  2. Beck WS. Leukocytes I. Physiology. In: Hematology, 5th ed. Beck WS (editor): Cambridge, MA: The Massachusetts Institute of Technology; 1991:339-57.

  3. Browder AA, Hoff JA, Perterdorf RG. The significance of fever in neoplastic disease. Ann Intern Med 1969;55:932-42.

  4. Klastersky J, Weerts D, Hensgens C. Fever of unexplained origin in patients with cancer. Eur J Cancer 1973;9:649-56.

  5. Pizzo PA, Robichaud JK, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine 1982;61:153-56.

  6. Boyer MJ, McGeer A, Feld R. Recent advances in the management of infections in cancer patients. Crit Rev Oncol Hematol 1993;15:175-90.

  7. Chanock SJ, Pizzo PA. Fever in the neutropenic host. Infect Dis Clin North Am 1996;10:777-96.

  8. Hathorn JW, Lyke K. Empirical treatment of febrile neutropenia. Evolution of current therapeutic approaches. Clin Infect Dis 1997;24(Suppl.2): S256-65.

  9. Savarese DM, Chung-cheng H, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematological malignancies and solid tumors. J Clin Oncol 1997;15:2981-95.

  10. Herzig RH, Herzig GP, Graw RG, Bull MI, Ray KK. Successful granulocyte transfusion therapy for Gram-negative septicemia. N Engl J Med 1977;296:701-5.

  11. Alavi JB, Root RK, Djerassi I, Evans AE, Gluckman SJ, MacGregor R, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med 1997;296:706-11.

  12. Vogler WR, Winton EF. A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med 1977;63:548-55.

  13. Winston DJ, Winston GH, Gale RP. Therapeutic granulocyte transfusions for documented infections. Ann Intern Med 1982;97:509-15.

  14. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991;325:81-6.

  15. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-16.

  16. Schimpff S. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80(Suppl. 5C):13-20.

  17. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamycin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061- 5.

  18. Pizzo PA, Ladisch S, Simon RM, Gill F, Levine AS. Increasing incidence of Gram-positive sepsis in cancer patients. Med Ped Oncol 1978;5:241-5.

  19. Wade JC, Schimpff SC, Newman KA, Wiernik PH. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1982;97:503- 8.

  20. Mueller BU, Skelton J, Callender DP, Marshall D, Gress J, Longo D, et al. A prospective randomized trial comparing the infectious and non-infectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 1992;10:1943-8.

  21. Philpott-Howard J. Management of infection in neutropenic patients. Curr Opin Infect Dis 1997;10:255-61. 21· Este artículo revisa el espectro de los patógenos actualmente aislados de pacientes neutropénicos y discute los patrones en desarrollo de resistencia a los agentes antimicrobianos.

  22. Phillips P. The use of azoles for treatment of fungal infections in cancer patients. Curr Oncol 1997;4(Suppl. 2):S16-S20.

  23. Pizzo PA. Management of fever in patients with cancer and treatment induce neutropenia. N Engl J Med 1993;328:1323-32.

  24. Hughes WT, Armstrong D, Bodey Gp, Feld R, Mandell GL, Meyers JD, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:281-396.

  25. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia. Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247-59. 25· Este análisis retrospectivo de los resultados de tratamiento en pacientes neutropénicos con cáncer en un solo centro identificó varios determinantes que pueden utilizarse como indicadores pronósticos.

  26. Klastersky J, Zinner SH. Synergistic combinations of antibiotics in Gram-negative bacillary infections. Rev Infect Dis 1982;4:294- 301.

  27. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients. A metaanalysis. J Infect Dis 1991;164:907-16.

  28. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramicin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994;120:834-44.

  29. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, et al. Monotherapy for fever and neutropenia in cancer patients. A randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-76.

  30. Shah PM, Heller A, Fuhr GH, Walther R, Halir S, Schaumann R, et al. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Infection 1996;24:480-4.

  31. Yamamura D, Gucalp R, Carisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamycin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997;41:1704-8.

  32. Calandra T, Zinner SH, Viscoli C, de Bock R, Gaya H, Meunier, et al. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.

  33. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Arch Intern Med 1988;148:2561-8.

  34. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia. A prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.

  35. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia. A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-14.

  36. Malik IA, Khan WA, Aziz Z, Karim M. Self-administered antibiotic therapy for chemo-therapy induced, low-risk, febrile neutropenia in patients with nonhematological neoplasms. Clin Infect Dis 1994;19:522-7.

  37. Malik IA, Khan WA, Karim M, Aziz Z, Khan A. Feasibility of outpatient management of fever in cancer patients with lowrisk neutropenia. Results of a prospective randomized trial. Am J Med 1995;98:224-31.

  38. Rubenstein EB, Rolston K, Benjamin, Loewy J, Escalante E, Manzullo E, et al. Outpatient treatment of febrile neutropenia in low-risk neutropenic patients with cancer. Cancer 1993;71:3840-6.

  39. Rolston KV, Rubenstein EB, Elting L, Escalante C, Mazullo E. Ambulatory management of febrile episodes in low-risk neutropenic patients [Abstract 2235]. Programs and Abstracts of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy; San Francisco, CA; Washington, DC; American Society of Microbiology; 1995:33.

  40. Tanner DJ. Cost containment of reconstituted parental antibiotics. Personnel and supply costs associated with preparation, dispensing and administration. Rev Infect Dis 1984;6:S924-37.

  41. Kibbler CC, Prentice HG. Which febrile neutropenic patients are suitable for outpatient management? Curr Opin Infect Dis 1997;10:251-4.

  42. Cruciani M, Rampzzo R, Malena, Lazzarini L, Todeschini, Messori A, Concia E. Prophylaxis with fluoroquinolones for bacterialinfections in neutropenic patients. A meta-analysis. Clin Infect Dis 1996;23:795-805.

  43. Rotstein C, Mandell LA, Goldberg N. Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients. A meta-analysis. Curr Oncol 1997;4(suppl. 2):S2-7. Este metanálisis revisa los datos disponibles en el uso rutina- rio de fluoroquinolonas en la prevención de infecciones en pacientes neutropénicos con cáncer y ayuda a clarificar este controvertido tema.

  44. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994;330:1241-2.

  45. Carratala J, Fernandez Sevilla A, Tubau F, Callis M, Gudiol R. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-60.

  46. Ball P. Is resistant Escherichia coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as prophylaxis? [Editorial response]. Clin Infect Dis 1995;20:561-3.

  47. Gotzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifugal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997;314:1238-44.

  48. Bow EJ. A review of the prophylactic efficacy of azole-based antifungal agents in neutropenic cancer patients receiving insensive chemotherapy. Curr Opin 1997;4:S11-5.

  49. Offner F. Hematopoietic growth factors in cancer patients with invasive fungal infections. Eur J Clin Microbiol Infect Dis 1997;16:56-63.

  50. ASCO Committee. American Society of Clinical Oncology recommendations for the use of hematopoietic colonystimulating factors. Evidence-based clinical practice guidelines. J Clin Oncol 1994;12:2471-508.

  51. Hartmann LC, Tschetter LK, Mabermann TM, Ebbert LP, Johnson SP, Maillard JA, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced a febrile neutropenia. N Engl J Med 1997;336:1776-80.

  52. ASCO Committee. Update of recommendations for the use of hematopoietic colony-stimulating factors. Evidence-based clinical practice guidelines. J Clin Oncol 1996;14:1957-60.

  53. Bennett CL, Smith TJ, Weeks JC, Bredt AB, Feinglass J, Fetting JH, et al. Use of hematopoietic colony-stimulating factors. The American Society of Clinical Oncology Survey. J Clin Oncol 1996;14:2511-20.

  54. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488-93.

  55. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.

  56. Kuo CC, Shor A, Campbell LA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-9.

  57. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med 1992;116: 273-8.

  58. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infection. Circulation 1997; 96:404-7.

  59. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology: A basic science for clinical medicine. 2nd ed. Boston: Little Brown, 1991.

  60. Muir Gray JA. Evidence-based healthcare. New York: Churchill Livingstone, 1997.

  61. Loeb DS, Talley NJ, Ahlquist DA, Carpenter HA, Zinsmeister AR. Gastroenterology 1992;102:1899-905.

  62. Taha AS, Sturrock RD, Russell RI. Gut 1995;36:334-6.

  63. Taha AS, Hudson N, Hawkey CJ, et al. N Engl J Med 1996; 334:1435-9.

  64. Silverstein FE, Graham DY, Senior JR, et al. Ann Intern Med 1995;123:241-9.




2020     |     www.medigraphic.com